Your browser doesn't support javascript.
loading
Protection against reinfection with SARS-CoV-2 omicron BA.2.75* sublineage
Hiam Chemaitelly; Patrick Tang; Peter Coyle; HADI M. YASSINE; Hebah A. Al Khatib; Maria K. Smatti; Mohammad R. Hasan; Houssein Ayoub; Heba N. Altarawneh; Zaina Al-Kanaani; Einas Al-Kuwari; Andrew Jeremijenko; Anvar Hassan Kaleeckal; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Hanan F. Abdul-Rahim; Gheyath Nasrallah; Mohamed Ghaith Al-Kuwari; Adeel A Butt; Hamad E. Al-Romaihi; Mohammed H. J. Al-Thani; Abdullatif Al-Khal; Roberto Bertollini; Laith J Abu-Raddad.
Afiliação
  • Hiam Chemaitelly; Weill Cornell Medicine-Qatar
  • Patrick Tang; Sidra Medicine
  • Peter Coyle; Hamad Medical Corporation
  • HADI M. YASSINE; Qatar University
  • Hebah A. Al Khatib; Qatar University
  • Maria K. Smatti; Qatar University
  • Mohammad R. Hasan; Sidra Medicine
  • Houssein Ayoub; Qatar University
  • Heba N. Altarawneh; Weill Cornell Medicine-Qatar
  • Zaina Al-Kanaani; Hamad Medical Corporation
  • Einas Al-Kuwari; Hamad Medical Corporation
  • Andrew Jeremijenko; Hamad Medical Corporation
  • Anvar Hassan Kaleeckal; Hamad Medical Corporation
  • Ali Nizar Latif; Hamad Medical Corporation
  • Riyazuddin Mohammad Shaik; Hamad Medical Corporation
  • Hanan F. Abdul-Rahim; Qatar University
  • Gheyath Nasrallah; Qatar University
  • Mohamed Ghaith Al-Kuwari; Primary Health Care Corporation
  • Adeel A Butt; Hamad Medical Corporation
  • Hamad E. Al-Romaihi; MoPH: Ministry of Public Health Qatar
  • Mohammed H. J. Al-Thani; MoPH: Ministry of Public Health Qatar
  • Abdullatif Al-Khal; Hamad Medical Corporation
  • Roberto Bertollini; MOPH: Ministry of Public Health Qatar
  • Laith J Abu-Raddad; Weill Cornell Medicine-Qatar
Preprint em Inglês | medRxiv | ID: ppmedrxiv-22281606
ABSTRACT
The BA.2.75* sublineage of SARS-CoV-2 B.1.1.529 (omicron) variant escapes neutralizing antibodies. We estimated effectiveness of prior infection in preventing reinfection with BA.2.75* using a test-negative, case-control study design. Effectiveness of prior pre-omicron infection against BA.2.75* reinfection, irrespective of symptoms, was 6.0% (95% CI 1.5-10.4%). Effectiveness of prior BA.1/BA.2 infection was 49.9% (95% CI 47.6-52.1%) and of prior BA.4/BA.5 infection was 80.6% (95% CI 71.2-87.0). Effectiveness of prior pre-omicron infection followed by BA.1/BA.2 infection against BA.2.75* reinfection was 56.4% (95% CI 50.5-61.6). Effectiveness of prior pre-omicron infection followed by BA.4/BA.5 infection was 91.6% (95% CI 65.1-98.0). Analyses stratified by time since prior infection indicated waning of protection since prior infection. Analyses stratified by vaccination status indicated that protection from prior infection is higher among those vaccinated, particularly among those ...
Licença
cc_no
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Estudo observacional Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Estudo observacional Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
...